The ACC launched its latest registry knowing that volumes at these outpatient facilities are expected to rise in the years ahead. 

TAVR continues to gain momentum as a go-to treatment option for severe AS, making it more important than ever to investigate long-term outcomes. This latest analysis, published in European Heart Journal, focused on 280 patients randomized to undergo either transcatheter or surgical aortic valve replacement.

The company, part of Johnson & Johnson MedTech, shared positive data from two different clinical trials at AF Symposium 2024 in Boston.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

Injuries to the esophagus remain a common complication associated with radiofrequency ablation procedures. New research suggests a device developed by S4 Medical could significantly reduce the risk of such injuries. 

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

A new 10 French percutaneous heart pump could help greatly reduce vascular complications and improve cardiogenic shock outcomes.

According to Abbott, its Volt system was specifically designed to address weaknesses seen in other first-generation PFA offerings.